About: Glioma, immunotherapeutic approaches   Goto Sponge  NotDistinct  Permalink

An Entity of Type : rdac:C10001, within Data Space : data.idref.fr associated with source document(s)

AttributesValues
type
dc:subject
  • Medicine
  • Immunology
  • Biomedicine
  • Cancer Research
  • Oncology
  • Cancer research
  • Biomedicine general
  • Gliomas -- Treatment
  • Immunotherapy -- methods
  • Glioma -- immunology
  • Glioma -- therapy
  • Gliomas -- Immunotherapy
  • Gliomes -- Aspect immunologique
  • Gliomes -- Immunothérapie
preferred label
  • Glioma, immunotherapeutic approaches
Language
Subject
dc:title
  • Glioma, immunotherapeutic approaches
Publishing director
note
  • Treatment of glioma is currently one of the most challenging problems in oncology, as well as in neurosurgery. Despite major advances in our understanding of the pathomechanism, diagnosis by imaging and the availability of powerful therapeutic tools, the life expectancy of patients with glioblastoma has only been slightly prolonged and a cure remains elusive. None of the currently available surgical tools, including operative microscopes, lasers and image-guided surgery, can enable the detection and removal of all of the tumor tissue. In recent years, however, the landscape has been changing immeasurably, and molecular studies over the past two decades have identified a variety of genetic aberrations that are specifically associated with individual types of gliomas. In addition, certain molecular abnormalities have been linked to therapy responses, thereby establishing clinical biomarkers and molecular targets, and the use of novel agents is being investigated. These agents have been specifically engineered to exert specific cytotoxicity against gliomas, either on their own as single agents or in combination with other modalities. Moreover, there has been an enormous surge of interest in the area of immunology and immunotherapy, which has been facilitated by our understanding of the molecular basis of gliomas. Although several kinds of immunotherapeutic trials have been undertaken, we still await a great breakthrough in terms of clinical efficacy to prolong the survival time of glioma patients
dc:type
  • Text
http://iflastandar...bd/elements/P1001
rdaw:P10219
  • 2012
has content type
is primary topic of
is rdam:P30135 of
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software